Drug safety evaluation of defibrotide

Pharmacologic and Compression Therapies for Postthrombotic Syndrome

(2012) Jacqueline M. Cohen et al.   CHEST

Update on the use of defibrotide

(2012) Tommasina Guglielmelli et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

(2012) Selim Corbacioglu et al.   LANCET

Defibrotide Interferes With Several Steps of the Coagulation-Inflammation Cycle and Exhibits Therapeutic Potential to Treat Severe Malaria

(2011) Ivo M.B. Francischetti et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The Incidence of Veno-Occlusive Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Has Diminished and the Outcome Improved over the Last Decade

(2011) Enric Carreras et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Veno-occlusive disease in pediatric patients affected by Wilms tumor

(2011) Simone Cesaro et al.   PEDIATRIC BLOOD & CANCER

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial

(2010) Paul G. Richardson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation

(2010) Marta Palomo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors

(2010) O. Ostrovsky et al.   BLOOD

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

(2010) A. Palumbo et al.   HAEMATOLOGICA

Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome

(2009) Jason A. Coppell et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan

(2009) Barbara Cappelli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study

(2009) Christian M. Zwaan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Insights into defibrotide: an updated review

(2009) F Morabito et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease

(2008) L. Benimetskaya et al.   BLOOD

Vascular disorders of the liver

(2008) Laurie D. DeLeve et al.   HEPATOLOGY